Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignant Plasma Cell Neoplasm”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00006019
What this trial is testing

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

Who this might be right for
LeukemiaLung CancerLymphoma+3 more
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00017069
What this trial is testing

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
CTI BioPharma
Early research (Phase 1)Study completedNCT00361049
What this trial is testing

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Who this might be right for
Cancer
Case Comprehensive Cancer Center 49
Large-scale testing (Phase 3)Study completedNCT00064038
What this trial is testing

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Who this might be right for
Multiple MyelomaPlasma Cell Neoplasm
SWOG Cancer Research Network 198
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439123
What this trial is testing

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT00006013
What this trial is testing

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Fox Chase Cancer Center 21
Not applicableEnded earlyNCT00651716
What this trial is testing

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+8 more
Vanderbilt-Ingram Cancer Center 150
Testing effectiveness (Phase 2)Study completedNCT00448357
What this trial is testing

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
UNC Lineberger Comprehensive Cancer Center 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390865
What this trial is testing

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439136
What this trial is testing

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Ended earlyNCT02991898
What this trial is testing

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaBurkitt LymphomaNatural Killer Cell Malignancies+15 more
Masonic Cancer Center, University of Minnesota 3
Testing effectiveness (Phase 2)Study completedNCT00089167
What this trial is testing

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439344
What this trial is testing

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 53
Testing effectiveness (Phase 2)Study completedNCT00002657
What this trial is testing

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Who this might be right for
LymphomaMultiple Myeloma and Plasma Cell Neoplasm
SWOG Cancer Research Network 20
Not applicableStudy completedNCT04409314
What this trial is testing

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of California, San Francisco 23
Testing effectiveness (Phase 2)Study completedNCT00003399
What this trial is testing

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
University of Maryland, Baltimore
Testing effectiveness (Phase 2)Study completedNCT00006379
What this trial is testing

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
Case Comprehensive Cancer Center 58
Testing effectiveness (Phase 2)Study completedNCT01529827
What this trial is testing

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+75 more
Roswell Park Cancer Institute 94
Testing effectiveness (Phase 2)Study completedNCT00482495
What this trial is testing

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439357
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 4
Next Page